Hematology and Coagulation | Warfarin Management - Adult - Inpatient
Warfarin Management - Adult - Inpatient Consensus Care Practice Guideline
Target Population: Adult inpatients receiving anticoagulation therapy with the oral vitamin K antagonist, warfarin
Full Guideline: Warfarin Management - Adult - Inpatient
Guideline Overview
• Target INR and duration of therapy are based on indication for warfarin use- see full guideline
• Risk factors which alter sensitivity to warfarin
• Monitoring considerations
• Warfarin dosing protocol with INR goal 2-3
• Warfarin dosing protocol with INR goal 2.5-3.5
• Laboratory monitoring
• Dose adjustments for drug interactions
• Factors that increase INR
• Factors that decrease INR
• Warfarin reversal
• Transitioning to outpatient management
• References- see full guideline for citations
Table 1: see full guideline for INR goals and recommended duration of therapy by indication (with link when ready)
Risk factors which alter sensitivity to warfarin
Table 2. Warfarin sensitivity factors
Increases sensitivity (usually require lower doses)
• Baseline (pre-warfarin) PT/INR (e.g. greater than 1.4)
• Advanced age (e.g. 60 years of age or older)
• Underweight (e.g. BMI less than 18kg/m2)
• Nutritional status (e.g. malnourished, low vitamin K intake/stores)
• Genetic factors (e.g. CYP2C9, VKORC1 phenotypes)
• Drug-drug interactions
• Hypoalbuminemia
• Ethnicity (Asian)
• Liver disease
• Thyroid Disease (e.g. hyperthyroidism, Graves’ disease)
• Heart Failure
• Febrile illness
• Prolonged vomiting and diarrhea
• Surgery and blood loss
• Cannabinoids
• Alcohol
• Drug interactions
Decrease warfarin sensitivity (may require higher doses)
• Enteral feedings
• High-vitamin K intake
• Estrogens
• Chewing tobacco
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Table 3. Monitoring Considerations
Table 3. Monitoring Considerations
• Signs and symptoms of thrombosis progression or bleeding
• PT/INR (daily during initiation or unstable, and at least weekly when stable)
• CBC without differential prior to warfarin initiation and then at least every 3 days
• Missed or held doses
• Drug-drug and drug-food interactions
• Nutrition
• Activity level
Table 4. Warfarin dosing protocol with INR Goal 2-3
High Sensitivity to Warfarin Low Sensitivity to Warfarin
INR Value Dose INR Value Dose
Day 1 <1.5 2.5 - 5 mg <1.5 5 - 7.5 mg
Day 2 <1.5
≥1.5
2.5 - 5 mg
0 - 2.5 mg
<1.5
≥1.5
5 - 7.5 mg
0 - 5 mg
Day 3 <1.5
1.5-1.9
2-2.5
≥2.6
5 mg
2.5 mg
1 mg
0 (no dose)
<1.5
1.5-1.9
2-2.5
≥2.6
7.5 mg
5 mg
2.5 mg
0 (no dose)
Day 4 <1.5
1.5-1.9
2-3
> 3
7.5 mg
5 mg
2.5 mg
0 - 1 mg
<1.5
1.5-1.9
2-3
>3
10 mg
7.5 mg
5 mg
0-2.5 mg
Day 5
<1.5
1.5-1.9
2-3
3-3.5
>3.5
10 mg
yesterday’s dose + 1 mg
yesterday’s dose
yesterday’s dose – 1 mg
0 (no dose)
<1.5
1.5-1.9
2-3
3-3.5
>3.5
12.5 mg
yesterday’s dose + 2.5 mg
yesterday’s dose
yesterday’s dose – 2.5 mg
0 (no dose)
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Table 5. Warfarin dosing protocol with INR Goal 2.5-3.5
High Sensitivity to Warfarin Low Sensitivity to Warfarin
INR Value Dose INR Value Dose
Day 1 < 1.5 2.5 - 5 mg < 1.5 5 - 7.5 mg
Day 2 < 1.5
≥ 1.5
2.5 - 5 mg
0 - 2.5 mg
< 1.5
≥ 1.5
5 - 7.5 mg
0 - 5 mg
Day 3 < 1.5
1.5-1.9
2.0-2.5
≥ 2.5
5 - 7.5 mg
5 mg
2.5 mg
0 ( no dose)
< 1.5
1.5-1.9
2.0-2.5
≥ 2.5
7.5 - 10 mg
7.5 mg
5 mg
0 (no dose)
Day 4 < 1.9
2.0-2.4
2.5-3.5
≥ 3.6
7.5 mg
5 mg
2.5 mg
0 - 1 mg
< 1.9
2.0-2.4
2.5-3.5
≥ 3.6
10 mg
7.5 mg
5 mg
0-2.5 mg
Day 5 < 1.9
2.0-2.4
2.5-3.5
3.6-4.0
≥ 4.0
10 mg
yesterday’s dose + 2.5 mg
yesterday’s dose
yesterday’s dose – 2.5 mg
0 (no dose)
< 1.9
2.0-2.4
2.5-3.5
3.6-4.0
≥ 4.0
12.5 mg
yesterday’s dose + 2.5 mg
yesterday’s dose
yesterday’s dose – 2.5 mg
0 (no dose)
Laboratory Monitoring
Baseline
Within the past 30 days • Baseline INR
• Pregnancy test*
• CBC without diff
*Pregnancy test is not needed if:
1. Are postmenopausal (12 months of amenorrhea in
a woman > 45 years old in the absence of other
biological or physiological causes)
2. Had a hysterectomy or bilateral salpingo-
oophorectomy
3. Have ovarian failure
4. Had a bilateral tubal ligation or other surgical
sterilization procedure
5. Are known to be pregnant
6. Have had a miscarriage or abortion in the last 7
days
7. Have given birth within the past 4 weeks
Within the past 90 days • ALT
• Creatinine
During Admission
Daily • INR If providing a daily warfarin dose
At least weekly • CBC without diff
• INR
If providing a weekly warfarin dose
After Discharge
Within 3-4 days • INR
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Dose Adjustment Recommendations for Common/Significant Warfarin-Drug Interactions
Medication INR check after starting Adjustment
Amiodarone Every 7 days Target a 25-50% weekly dose reduction over 2-4 weeks
Rifampin Every 7 days Target a 50% weekly dose increase over 2 weeks
Fluconazole 2 – 3 days Target a 30% weekly dose decrease
Metronidazole 2 – 3 days Target a 30% weekly dose decrease
Sulfamethoxazole/
Trimethoprim
2 days
Target a 30% weekly dose decrease
Should reduce dose prior to starting medication to
avoid critical INR elevation
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Table 6. Medications, Dietary Supplements, and Foods that INCREASE INR or bleeding risk
Drug Class Known Interaction Probable Interaction Possible Interaction Unlikely Interaction
Anti-Infective Ciprofloxacin
Erythromycin
Fluconazole*
Isoniazid
Metronidazole*
Miconazole
Miconazole Vaginal
Suppository
Moxifloxacin
Sulfamethoxazole*
Voriconazole
Amoxicillin/clavulanate
Azithromycin
Clarithromycin
Itraconazole
Ketoconazole
Levofloxacin
Ritonavir
Tetracycline
Amoxicillin
Chloramphenicol
Darunavir
Daptomycin
Etravirine
Ivermectin
Nitrofurantoin
Norfloxacin
Ofloxacin
Saquinavir
Telithromycin
Terbinafine
Cefotetan
Cefazolin
Tigecycline
Cardiovascular Amiodarone*
Clofibrate
Diltiazem
Fenofibrate
Propafenone
Propranolol
Aspirin
Fluvastatin
Quinidine
Ropinirole
Simvastatin
Disopyramide
Gemfibrozil
Metolazone
Analgesics, Anti-
Inflammatory
Piroxicam Acetaminophen
Aspririn
Celecoxib
Tramadol
Indomethacin
Propoxyphene
Sulindac
Tolmentin
Topical Salicylates
Methylprednisolone
Nabumetone
CNS Drugs Alcohol
Citalopram
Entacapone
Sertraline
Disulfiram
Chloral hydrate
Fluvoxamine
Phenytoin
Felbamate Diazepam
Fluoxetine
Quetiapine
GI Drugs and
Food
Cimetidine
Mango
Omeprazole
Grapefruit Orlistat
Herbal
Supplement
Fenugreek
Feverfew
Fish Oil
Ginkgo
Quilinggao
Dandelion
Danshen
Don Quai
Lycium
PC-SPES
Red or Sweet Clover
Capsicum
Forskolin*
Garlic
Ginger
Turmeric
Other Anabolic Steroids
Capecitabine
Zileuton
Fluorouracil
Gemcitabine
Levamisole
Paclitaxel
Tamoxifen
Tolterodine
Acarbose
Cyclophosphamide
Danazol
Iphosphamide
Trastuzumab
Etoposide
Carboplatin
Levonorgestrel
*Indicates significant interaction
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Table 7. Medications, Dietary Supplements, and Foods that DECREASE INR
Drug Class Known Interaction Probable Interaction Possible
Interaction
Unlikely
Interaction
Anti-Infective Griseofulvin
Nafcillin
Ribavirin
Rifampin*
Dicloxacillin
Ritonovir
Rifapentine
Terbinafine
Nelfinavir
Nevirapine
Cloxacillin
Rifaximin
Teicoplanin
Cardiovascular Cholestyramine Bosentan Telmisartan Furosemide
Analgesics, Anti-
Inflammatory
Mesalamine Azathioprine Sulfasalazine
CNS Drugs Barbiturates
Carbamazepine
Chlordiazepoxide Propofol
GI Drugs and
Food
High content
vitamin K food
Avocado
Soy milk
Sucralfate
Sushi containing
seaweed
Herbal
Supplement
Alfalfa Ginseng
Multivitamin
St. John’s Wort
Parsley
Chewing Tobacco
Co-Enzyme Q10
Yarrow
Licorice
Green Tea
Other Mercaptopurine Chelation Therapy
Influenza vaccine
Raloxifene
Cyclosporine
Etretinate
Ubidecarenone
*Indicates significant interaction
Click here for information on Warfarin Reversal
Transitioning to outpatient management
Communication to
the next provider of
care
Indication
Target INR range
Warfarin dose
Date for next INR check
Name of the clinic or provider assuming warfarin management
Length of therapy
Potential drug, herbal, or supplement interactions
Longitudinal record of inpatient INR values and warfarin doses
Bridging therapy if needed
Educational materials provided to the patient
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
References
1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.
2. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S.
3. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med.
2018;379(13):1290.
4. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and
prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):53S-70S.
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial
fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice
guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-267.
6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline
for the Management of Patients With Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol. 2019;74(1):104-132.
7. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S-e636S.
8. Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis:
a statement for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke. 2011;42(4):1158-1192.
9. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e419S-e496S.
10. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel
Report. Chest. 2016;149(2):315-352.
11. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular
disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S-e600S.
12. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for
the Management of Patients With Valvular Heart Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation.
2017;135(25):CIR.000000000000.
13. Puskas JD, Gerdisch M, Nichols D, et al. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic
Valve Replacement. J Am Coll Cardiol. 2018;71(24):2717-2726.
14. Saito Y, Nazif T, Baumbach A, et al. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis
Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2019.
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
15. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients.
N Engl J Med. 2011;364(23):2187-2198.
16. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who
cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.
17. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding
prosthesis. N Engl J Med. 2014;370(19):1790-1798.
18. Falk V, Baumgartner H, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur J Cardiothorac Surg. 2017;52(4):616-664.
19. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American academy of orthopaedic surgeons clinical practice
guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee
arthroplasty. J Bone Joint Surg Am. 2009;91(7):1756-1757.
20. Britt RP, James AH, Raskino CL, Thompson SG. Factors affecting the precision of warfarin treatment. J Clin
Pathol. 1992;45(11):1003-1006.
21. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin
therapy. Ann Intern Med. 1992;116(11):901-904.
22. Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of Age on Warfarin Dose, Anticoagulation
Control, and Risk of Hemorrhage. Pharmacotherapy. 2018;38(6):588-596.
23. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin
Pharmacol. 1977;4(3):315-320.
24. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response
to warfarin. Clin Pharmacol Ther. 2004;75(3):204-212.
25. Gladman JR, Dolan G. Effect of age upon the induction and maintenance of anticoagulation with warfarin.
Postgrad Med J. 1995;71(833):153-155.
26. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin
Hosp Pharm. 1983;8(1):75-77.
27. Redwood M, Taylor C, Bain BJ, Matthews JH. The association of age with dosage requirement for warfarin. Age
Ageing. 1991;20(3):217-220.
28. Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, Hillman MA. Impact of age, CYP2C9 genotype and
concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
Clin Med Res. 2005;3(4):207-213.
29. Warfarin (Coumadin®) [prescribing information]. Brisol-Meyers Squibb, Inc.; Princeton, NJ. 2010.
30. Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial warfarin response in obese patients versus non-
obese patients. J Thromb Thrombolysis. 2013;36(1):96-101.
31. Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson NL. Warfarin dosing and body mass index. Ann
Pharmacother. 2014;48(5):584-588.
32. Abdelhafiz AH, Myint MP, Tayek JA, Wheeldon NM. Anemia, hypoalbuminemia, and renal impairment as
predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial
fibrillation: a secondary analysis. Clin Ther. 2009;31(7):1534-1539.
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
33. Yoshizawa M, Hayashi H, Tashiro Y, et al. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and
serum albumin alterations on warfarin response in Japanese patients. Thromb Res. 2009;124(2):161-166.
34. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann
Pharmacother. 2005;39(6):1008-1012.
35. Zhang H, De T, Zhong Y, Perera MA. The advantages and challenges of diversity in Pharmacogenomics: Can
minority populations bring us closer to implementation? Clinical Pharmacology & Therapeutics. 2019.
36. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J
Am Coll Cardiol. 2018;71(19):2162-2175.
37. Howard-Thompson A, Luckey A, George C, Choby BA, Self TH. Graves’ Disease and Treatment Effects on Warfarin
Anticoagulation. Case Reports in Medicine. 2014;2014:1-6.
38. Busenbark LA, Cushnie SA. Effect of Graves' disease and methimazole on warfarin anticoagulation. Ann
Pharmacother. 2006;40(6):1200-1203.
39. Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in
hyperthyroidism. Q J Med. 1986;58(225):43-51.
40. Self TH, Straughn AB, Weisburst MR. Effect of hyperthyroidism on hypoprothrombinemic response to warfarin.
Am J Hosp Pharm. 1976;33(4):387-389.
41. Self TH, Reaves AB, Oliphant CS, Sands C. Does heart failure exacerbation increase response to warfarin? A
critical review of the literature. Curr Med Res Opin. 2006;22(11):2089-2094.
42. del Campo M, Roberts G. Changes in Warfarin Sensitivity During Decompensated Heart Failure and Chronic
Obstructive Pulmonary Disease. Ann Pharmacother. 2015;49(9):962-968.
43. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary
supplements. Expert Opin Drug Saf. 2006;5(3):433-451.
44. Dickerson RN, Garmon WM, Kuhl DA, Minard G, Brown RO. Vitamin K-independent warfarin resistance after
concurrent administration of warfarin and continuous enteral nutrition. Pharmacotherapy. 2008;28(3):308-313.
45. Klang M, Graham D, McLymont V. Warfarin bioavailability with feeding tubes and enteral formula. JPEN J
Parenter Enteral Nutr. 2010;34(3):300-304.
46. Dickerson RN. Warfarin Resistance and Enteral Tube Feeding: An Old Problem With a New Solution.
2008;43(6):520-524. https://doi.org/10.1310/hpj4306-520.
47. Petretich DA. Reversal of osmolite-warfarin interaction by changing warfarin administration time. Clin Pharm.
1990;9(2):93.
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.
Copyright © 2021 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission
Contact: CCKM@uwhealth.org Last Revised: 07/2021
Effective 5-20-2021. Contact CCKM@uwhealth.org for previous versions.